1. Home
  2. MTB vs INSM Comparison

MTB vs INSM Comparison

Compare MTB & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo M&T Bank Corporation

MTB

M&T Bank Corporation

N/A

Current Price

$224.94

Market Cap

31.3B

Sector

Finance

ML Signal

N/A

Logo Insmed Incorporated

INSM

Insmed Incorporated

N/A

Current Price

$149.57

Market Cap

35.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MTB
INSM
Founded
1856
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.3B
35.2B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
MTB
INSM
Price
$224.94
$149.57
Analyst Decision
Buy
Strong Buy
Analyst Count
20
23
Target Price
$222.55
$188.73
AVG Volume (30 Days)
1.2M
2.2M
Earning Date
01-01-0001
05-21-2026
Dividend Yield
2.70%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.95
$130.70
Revenue Next Year
$3.75
$74.05
P/E Ratio
$13.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$150.75
$60.40
52 Week High
$239.00
$212.75

Technical Indicators

Market Signals
Indicator
MTB
INSM
Relative Strength Index (RSI) 52.62 39.89
Support Level $178.77 $139.81
Resistance Level $239.00 $149.08
Average True Range (ATR) 5.42 6.89
MACD -1.88 0.82
Stochastic Oscillator 38.13 21.35

Price Performance

Historical Comparison
MTB
INSM

About MTB M&T Bank Corporation

M&T Bank is a US regional bank with roughly $210 billion in assets as of June 30, 2025. Headquartered in Buffalo, New York, the bank's footprint is mostly concentrated in New England and the US Mid-Atlantic. M&T Bank boasts a community banking approach, and boasts over 900 branches in 13 states and Washington, D.C. Apart from retail and commercial banking, M&T Bank also has wealth management operations through Wilmington Trust and a partnership with LPL Financial, and a corporate trust businesses.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: